François Lescure, General Manager of Invectys SAS, to Participate in The Abbvie Partnering Day in Paris, France on October 4th, 2022

On September 22, 2022 Invectys Inc. is a clinical-stage immunotherapy company reported to the development of a new generation of products for cancer patients (Press release, Invectys, SEP 22, 2022, View Source [SID1234621299]). Headquartered in Houston and with R&D facilities in Paris, Invectys will participate in the Abbvie Partnering Day in Paris, France, on October 4th, 2022, announced François Lescure, General Manager of its R&D branch in France.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!